Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioAge Labs, obesity
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.
Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO
Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.
IPO, MNTN and Ryan Reynolds
Ryan Reynolds's MNTN Explores Going Public as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, including Reynolds' MNTN.
Ryan Reynolds’s ad tech firm MNTN looks to Morgan Stanley for 2025 IPO
MNTN, a company that sells targeted TV advertising technology, may be working with Morgan Stanley on an initial public offering (IPO) as the firm considers its future. MNTN has already expanded significantly in recent years acquiring Hollywood star Ryan Reynolds’s agency,
Ryan Reynolds’ MNTN Is Said to Tap Morgan Stanley for 2025 IPO
MNTN, a connected TV advertising platform that counts Hollywood star Ryan Reynolds as its chief creative officer, has picked Morgan Stanley to work on an initial public offering, according to people familiar with the matter.
FierceBiotech
2d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
6h
U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up
Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.
2d
BioAge seeks nearly $200 million in initial public offering
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
IDF: Hezbollah leader killed
Helene: How to help
Houthis attack US warships
Congressional Gold Medal
NC dam failure ‘imminent’
Dow closes at record high
Haney sues Garcia
'Harry Potter' star dies
High-end brothel plea
ICE: Convicts roaming free
Van Gogh paintings attacked
Troops to leave some bases
NY ballot appeal rejected
Meta hit with privacy fine
Deposition in AI suit
Diocese reaches settlement
Promotes watch collection
Bill to use birth control
KY sues Express Scripts
Fed inflation gauge cools
US charges three Iranians
ISR targets Hezbollah HQ
Urgent safety alert for 737s
Ending password-sharing
50/50 ball ownership suit
Fake Biden robocalls fine
Producing doc on Diddy
Killer gets life sentence
Boxes to distribute Narcan
Pleads not guilty
Related topics
Initial public offering
U.S. Securities and Exchange Commission
BKV
Barnett Shale
Feedback